Ebola vaccine R&D: Filling the knowledge gaps
Donata Medaglini, Ali M Harandi, Tom H M Ottenhoff, Claire-Anne Siegrist, VSV-Ebovac Consortium, Selidji Todagbe Agnandji, Raf Ahmed, Jenna Anderson, Floriane Auderset, Luisa Borgianni, Jessica Brosnahan, Annalisa Ciabattini, Olivier Engler, Marielle C Haks, Gray Heppner, Alice Gerlini, Peter Gottfried Kremsner, Stephen Leib, Thomas Monath, Francis Ndungu, Patricia Njuguna, Mark Page, Gianni Pozzi, Rino Rappuoli, Francesco Santoro, Marc Strasser, Donata Medaglini, Ali M Harandi, Tom H M Ottenhoff, Claire-Anne Siegrist, VSV-Ebovac Consortium, Selidji Todagbe Agnandji, Raf Ahmed, Jenna Anderson, Floriane Auderset, Luisa Borgianni, Jessica Brosnahan, Annalisa Ciabattini, Olivier Engler, Marielle C Haks, Gray Heppner, Alice Gerlini, Peter Gottfried Kremsner, Stephen Leib, Thomas Monath, Francis Ndungu, Patricia Njuguna, Mark Page, Gianni Pozzi, Rino Rappuoli, Francesco Santoro, Marc Strasser
Abstract
With an emphasis on systems analyses, the VSV-EBOVAC project harnesses state-of-the-art technologies that illuminate mechanisms behind the observed immunogenicity and reactogenicity of the rVSV-ZEBOV vaccine and ensures that such information is shared among stakeholders.
Trial registration: ClinicalTrials.gov NCT02283099 NCT02287480 NCT02296983.
Copyright © 2015, American Association for the Advancement of Science.
Figures
Source: PubMed